Dengue Vaccine Efficacy and Side Effects
The recombinant tetravalent dengue vaccine (CYD-TDV/Dengvaxia) should only be used in dengue-seropositive individuals aged 9 years and older, as it significantly increases the risk of severe dengue and hospitalization in seronegative recipients, while providing strong protection (75% overall efficacy) in those with prior dengue exposure.
Critical Safety Distinction by Serostatus
Seropositive Individuals (Prior Dengue Exposure)
The vaccine demonstrates robust efficacy in those with previous dengue infection 1:
Efficacy Profile:
- Overall protection: 75.4% against virologically confirmed dengue over 5 years
- Serotype-specific efficacy: 70.2% (DENV-1), 67.9% (DENV-2), 77.5% (DENV-3), 89.9% (DENV-4) 2
- Hospitalization reduction: 68% (hazard ratio 0.32) 1
- Protection against severe dengue is substantial and sustained
Age-dependent efficacy in seropositive children increases progressively 2:
- Ages 6-8 years: 65.6% efficacy
- Ages 9-11 years: 73.4% efficacy
- Ages ≥12 years: 80.6% efficacy
Seronegative Individuals (No Prior Dengue Exposure)
This is where the critical safety concern emerges 1:
Increased Risk Profile:
- 5-year cumulative hospitalization rate: 3.06% in vaccinated seronegatives vs. 1.87% in unvaccinated controls
- Hazard ratio for hospitalization: 1.75 (75% increased risk)
- Similar trends toward higher risk of severe dengue
- Only modest protection against DENV-4 (51.2%); no significant efficacy against other serotypes 2
For seronegative children aged 9-16 years specifically:
- Hospitalization rate: 1.57% (vaccinated) vs. 1.09% (controls)
- Hazard ratio: 1.41 (though confidence interval crosses 1.0)
Common Side Effects
The vaccine is generally well tolerated with predominantly mild-to-moderate reactions 3, 4:
Most Common:
- Pain at injection site (6.3% after first dose, decreasing with subsequent doses)
- Headache
- Transient local reactions
Important Safety Notes:
- No serious adverse events were vaccine-related in clinical trials 3
- No immediate unsolicited adverse events reported
- Safety profile maintained through 4 years of follow-up 5
Clinical Algorithm for Use
Step 1: Determine Serostatus
- Mandatory serological testing before vaccination
- Use dengue anti-NS1 IgG ELISA or PRNT50 testing
- Only proceed if seropositive
Step 2: Age Verification
- Patient must be ≥9 years old (approved range 9-45 or 9-60 years depending on country) 5
- Children under 9 years have shown concerning safety signals, particularly ages 2-5 years 1
Step 3: Geographic Consideration
- Use only in high dengue endemic areas where baseline seroprevalence in 9-year-olds exceeds 60%
- WHO SAGE recommends integration into comprehensive dengue prevention strategies 5
Step 4: Dosing Schedule
- Three subcutaneous doses at 0,6, and 12 months 3
Critical Pitfalls to Avoid
Never vaccinate seronegative individuals - This is the most important contraindication based on the increased hospitalization risk demonstrated in the pivotal trials 1
Do not use in children under 9 years - Excess hospitalizations were specifically observed in the 2-5 year age group 1
Do not skip serological testing - The risk-benefit profile is completely reversed between seropositive and seronegative populations
Avoid use in low-transmission settings - The vaccine's benefit diminishes and safety concerns increase when baseline seroprevalence is low
Evidence Quality Note
The most robust evidence comes from the 2018 New England Journal of Medicine post-hoc analysis 1 that reanalyzed three phase 3 efficacy trials using improved serological testing methods. This study definitively established the serostatus-dependent safety profile that now guides all vaccination recommendations. The evidence is consistent across multiple high-quality studies 2, 5, with no contradictory findings regarding the increased risk in seronegative recipients.